ProCure Proton Therapy Center in Somerset reached a major milestone when its 2,000th patient completed cancer treatment.
The 2,000th graduate was Henri Delmar, a resident of Brentwood, New York, who was treated for prostate cancer. The occasion was celebrated with a graduation ceremony on June 15.
According to the American Cancer Society, prostate cancer is the second most common cancer among men in the United States, and about out in seven will be diagnosed with the illness during his lifetime.
Proton therapy is a precise form of radiation that directly attacks tumors while minimizing potentially damaging radiation to surrounding healthy tissues and organs, and is beneficial for difficult-to-reach tumors and complex cases, according to a statement prepared by ProCure. Like standard radiation, proton therapy destroys cancer cells by preventing them from dividing and growing. Proton therapy’s clinical advantage is its ability to reduce damage to healthy surrounding tissue, potentially allowing patients to receive radiation treatment with fewer side effects, the statement said.
Proton therapy has been used for more than 20 years to treat prostate cancer, and long-term data have proven its safety and efficacy. Recent studies have shown that proton therapy eliminates up to 60 percent of excess radiation delivered to healthy tissues surrounding the prostate compared to standard X-ray therapies, according to the statement.
For more information on ProCure, call 1-877-967-7628 or visit www.procure.com/nj.